S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Biden’s $374B Giveaway Into This Sector (Ad)
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
Bitcoin Rockets To Record High But Buy THIS Instead (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Biden’s $374B Giveaway Into This Sector (Ad)
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
Bitcoin Rockets To Record High But Buy THIS Instead (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Biden’s $374B Giveaway Into This Sector (Ad)
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
Bitcoin Rockets To Record High But Buy THIS Instead (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Biden’s $374B Giveaway Into This Sector (Ad)
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
Bitcoin Rockets To Record High But Buy THIS Instead (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Free Trial

Antibe Therapeutics (ATE) Earnings Date, Estimates & Call Transcripts

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)
Free ATE Stock Alerts
C$0.30
0.00 (0.00%)
(As of 04/18/2024 ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider Trades

Earnings Summary

Upcoming
Earnings Date
Jul. 4Estimated
Actual EPS
(Feb. 14)
-C$0.08 Beat By C$0.04
Consensus EPS
(Feb. 14)
-C$0.12
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

ATE Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

ATE Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Antibe Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20241C($0.11)C($0.11)C($0.11)
Q2 20242C($0.12)C($0.12)C($0.12)
Q3 20242C($0.12)C($0.11)C($0.12)
Q4 20242C($0.14)C($0.09)C($0.12)
FY 20247C($0.49)C($0.43)C($0.46)
Q1 20251C($0.11)C($0.11)C($0.11)
Q2 20251C($0.11)C($0.11)C($0.11)
Q3 20251C($0.15)C($0.15)C($0.15)
Q4 20251C($0.18)C($0.18)C($0.18)
FY 20254C($0.55)C($0.55)C($0.55)

ATE Earnings Date and Information

Antibe Therapeutics last announced its earnings results on February 14th, 2024. The reported C($0.08) EPS for the quarter, beating the consensus estimate of C($0.12) by C$0.04. Antibe Therapeutics has generated C($0.35) earnings per share over the last year (C($0.35) diluted earnings per share). Antibe Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, July 4th, 2024 based off prior year's report dates.

Antibe Therapeutics Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
7/4/2024
Estimated)		------- 
2/14/2024Q3 2024C($0.12)C($0.08)+C$0.04C($0.08)--
11/13/2023Q2 2024C($0.12)C($0.10)+C$0.02C($0.10)--
8/14/2023Q1 2024C($0.11)C($0.11)-C($0.11)--
6/29/2023Q4 2023C($0.09)C($0.06)+C$0.03C($0.06)--
2/14/2023Q3 2023C($0.12)C($0.08)+C$0.04C($0.08)--
11/14/2022Q2 2023C($0.11)C($0.12)C($0.01)C($0.12)--
8/15/2022Q1 2023C($0.11)C($0.10)+C$0.01C($0.10)--
6/29/2022Q4 2022-C($0.11)C($0.11)C($0.11)--
2/14/2022Q3 2022C($0.16)C($0.10)+C$0.06C($0.11)--
11/16/2021Q2 2022C($0.15)C($0.17)C($0.02)C($0.17)C$2.86 millionC$2.76 million
8/16/2021Q1 2022C($0.17)C($0.13)+C$0.04C($0.13)C$2.20 millionC$2.73 million
6/28/2021Q4 2021C($0.06)C($0.14)C($0.08)C($0.14)C$10.63 millionC$2.95 million

Antibe Therapeutics Earnings - Frequently Asked Questions

When is Antibe Therapeutics's earnings date?

Antibe Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, July 4th, 2024 based off last year's report dates. Learn more on ATE's earnings history.

Did Antibe Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Antibe Therapeutics (TSE:ATE) reported C($0.08) earnings per share (EPS) to beat the analysts' consensus estimate of C($0.12) by C$0.04. Learn more on analysts' earnings estimate vs. ATE's actual earnings.

How much revenue does Antibe Therapeutics generate each year?

Antibe Therapeutics (TSE:ATE) has a recorded annual revenue of C$9.71 million.

How much profit does Antibe Therapeutics generate each year?

Antibe Therapeutics (TSE:ATE) has a recorded net income of -C$18.24 million. ATE has generated -C$0.35 earnings per share over the last four quarters.


More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (TSE:ATE) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Biden’s $374B Giveaway Into This Sector
DTI
SHOCKING Crypto Leak…
Crypto 101 Media
He Is Giving Away Bitcoin
Crypto Swap Profits
The #1 Crypto for 2024
InvestorPlace
Options trading has suddenly become more reliable.
Eagle Publishing
How Biden has already won 2024
Porter & Company
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
Urgent alert: open this for a huge profit potential
Timothy Sykes